Daiwa: Reiterates "Buy" rating on TRIP.COM-S (09961), target price HK$508
In the second quarter, international OTA platform revenue grew by over 50% year-on-year, contributing about 20% of total revenue, while inbound travel revenue also recorded high double-digit year-on-year growth.
Daiwa released a research report stating that TRIP.COM-S (09961) announced its second-quarter results for this year. The firm remains constructive on the company's long-term prospects, as international business is becoming a new growth engine, and it is encouraged by management's accelerated execution of share buybacks; at 11.7x 12-month forward P/E, about 40% below the three-year average of 19.8x, the firm views the risk-reward as attractive. It reiterates a "Buy" rating and a 12-month target price of HK$508.
The report noted that the company's second-quarter results showed total revenue of RMB15.663 billion, up 5.5% year on year; adjusted operating income of RMB4.365 billion, and adjusted net profit of RMB4.798 billion. On the other hand, second-quarter revenue from the international OTA platform grew more than 50% year on year, contributing about 20% of revenue, while inbound tourism revenue also recorded high double-digit year-on-year growth; management said Trip.com's contribution margin has turned positive. The firm expects third-quarter total revenue to grow 2% year on year to RMB18.8 billion, with an adjusted operating margin of 31%; it also expects the share count to continue declining in the second half, which will provide downside support for the stock price.
Related Articles

General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint

RECOMMEND





